OmniAb®

OmniAb, Inc.

Nasdaq: OABI

August 2025

Disclaimer

We caution you that this presentation contains forward-looking statements.

All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, including our financial guidance for 2025, business strategy, our expectations regarding the application of, and the rate and degree of market acceptance of, our technology platform and other technologies, our or our partners' expectations regarding the addressable markets for our technologies or their product candidates, as applicable including the growth rate of the markets in which we operate, our competitive advantage and the growth prospects of our business, the scalability of our business, our ability to leverage the growth of our business and to do so efficiently, the timing of the initiation or completion of preclinical studies and clinical trials by our partners, expectations regarding potential safety and therapeutic benefits of our partners' product candidates, whether they could be first-in-class or best-in-class, product approvals and potential for future revenue growth, launches by our partners and the timing thereof, the anticipated introduction of new technologies and innovations and enhancement of our technology stack and partners' experiences, the continued innovation around and the expected performance of our technologies and the opportunities and earnings and cash flow accretion they may create, including the xPloration Partner Access Program, the ability to add new partners and programs, the scientific presentations and clinical and regulatory events of our partners and the timing thereof, and the potential for and timing of receipt of milestones and royalties under our license agreements with partners, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Actual results may differ from those set forth in this presentation due to the risks and uncertainties inherent in our business, including, without limitation: our future success is dependent on acceptance of our technology platform and technologies by new and existing partners, as well as on the eventual development, approval and commercialization of products developed by our partners for which we have no control over the development plan, regulatory strategy or commercialization efforts; biopharmaceutical development is inherently uncertain, risks arising from changes in technology; the competitive environment in the life sciences and biotechnology platform market; risks associated with quality and timing in manufacturing our xPloration instruments and related consumables and our reliance on a limited number of third-party manufacturers and suppliers; our failure to maintain, protect and defend our intellectual property rights; difficulties with performance of third parties we will rely on for our business; government healthcare reform, legislative measures and regulatory developments in the United States and foreign countries; unstable market and economic conditions, may have serious adverse consequences on our business, financial condition and stock price; we may use our capital resources sooner than we expect; and other risks described in our press releases and filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made, and except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Information regarding partnered products and programs comes from reports or information publicly released by our partners and have not been independently verified by OmniAb. For our definitions of "active partners," "active programs," "active clinical programs and approved products" and "approved products", see "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 18, 2025.

This presentation also contains estimates and other statistical data made by independent parties and by us and/or our partners relating to market size and growth and other data about the antibody industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

Our Business

LEVERAGING OUR PROPRIETARY DISCOVERY TECHNOLOGY PLATFORM WORLDWIDE

Technology Offering Addresses Most Critical Challenges of Discovery

Create, Screen, Deliver antibodies leveraging industry's only 4-species platform with differentiated tech and core competencies

One of the Largest Greenfields in the Pharma Industry

Total addressable market for antibodies expected to surpass $330 billion in 2029

POISED FOR GROWTH BY MEETING A GLOBAL INDUSTRY NEED

Leading, Proven and Leverageable Technology

Growing numbers of partners and programs

Innovation and Intelligent Expansion of Our Technology

New technology launches and an increasingly efficient internal technology innovation engine

Sources: Clarivate Analytics Cortellis database

Mission

Our mission is to enable the rapid development of innovative therapeutics by **pushing the frontiers of drug discovery technologies**.

OmniAb

Demand for Discovery Technology is Increasing

Higher industry success rates and other factors are driving an acceleration of antibody-based investment by the pharmaceutical industry

Higher Success Rates *vs.* Small Molecules

Historical overall regulatory approval success rates for antibodies have been significantly higher than for small molecules (12.1% *vs.* 7.5%).(1)

Inflation Reduction Act (IRA)

Provision for drug price negotiations between Medicare and drug makers

Small molecule drugs are eligible for negotiation 7 years after approval while large molecule are not eligible until 11 years after approval.

In a PhRMA survey of biopharmaceutical companies, 63% said they expect to shift R&D investment away from small molecule medicines as a result of the IRA.(2)

Number of Antibody Therapeutics Granted First Approval in the US or EU (2005 - 2024)[3]



ANTIBODY SOCIETY

(1) BIO | QLS Advisors | Informa Feb 2021 Report; Applied Clinical Trials
(2) phrma.org; https://phrma.org/en/Blog/WTAS-Inflation-Reduction-Act-already-impacting-RD-decisions
(3) The Antibody Society Database of Antibody Regulatory Approvals, December 31, 2024; Antibody therapeutics approved or in regulatory review in the EU or US - The Antibody Society

OmniAb

Value Creation Cycle

SOURCES OF FUTURE CASH FLOWS AND VALUE-GENERATION WITHIN A LEVERAGEABLE BUSINESS

OUR NOVEL PLATFORM TECHNOLOGIES
Built to address key industry needs

NEW & EXISTING PARTNERSHIPS

NEW TECH INNOVATION & STRATEGIC OPPORTUNITIES
Established track record of success in novel technology launches, efficient and focused M&A, and leveraging our technologies in creative ways to drive value

ADDITIONS TO PIPELINE
Active Programs growing at double-digit rates over recent years

CLINICAL-STAGE PROGRAMS
Key programs coming into focus, showing potential for significant differentiation

OmniAb®

CONTRACTED POTENTIAL MILESTONES
Over $3 billion in contracted potential milestones for antibody-based programs

ROYALTY ASSETS

Continued validation via our Development and Commercial Programs also drives additions to pipeline

FUNDAMENTAL ELEMENTS OF VALUE FOR ROYALTY ASSETS

Partner	Program → Product	Potential
Scope • Scale • Therapy-Area Expertise • Specific R&D Spend	Novelty • Clinical Validation Differentiation	# of Geographies • # of Indications Competitive Position • Product Pricing

Any of these elements can drive significant value at various points in a program or product lifecycle

Select OmniAb Partners

AMGEN

Boehringer Ingelheim

Genmab

Johnson&Johnson Innovative Medicine

MERCK

MERCK

NEUROCRINE BIOSCIENCES

ONO PHARMACEUTICAL CO.,LTD.

Pfizer

sanofi

symphogen a Servier Company

Takeda

Active Partners

Q2 2025: 100 ACTIVE PARTNERS



- We continue to grow and diversify our partnership base, with 100 Active Partners as of 6/30/2025
- New licenses added in Q2 include those with Veraxa Biotech AG, Duke-NUS, University of Maryland, AB-Ray Bio, and an undisclosed global CRO, and an asset deal with Angelini Pharma
- On pace for one of our strongest years ever in new partner additions

See our SEC filings for Active Partners definition
Partner location based on partner headquarters

OmniAb

Active Programs

Q2 2025: 381 ACTIVE PROGRAMS





- 381 Active Programs as of 6/30/2025
- Strong 1H 2025 for additions, balanced by attrition
- Net addition of 18 programs year-to-date, more than double the net additions in 1H 2024

See our SEC filings for Active Program definition

OmniAb

Active Programs and Potential Downstream Economics



- ~99% of Active Programs have contracted future economics to OmniAb
- Total remaining milestones for Antibody Standard Licenses: >$3 Billion(1)
- Average royalty rate for Antibody Standard Licenses: 3.36%(1)

(1) Calculated for Active Programs as of 6/30/25. Excludes prepaid licenses and grandfathered licenses, small molecule ion channel programs, and programs from Academic Partner/Revenue Share licenses where the economics to OmniAb are not yet known. For programs with tiered royalties, the royalty rate is calculated as a blended royalty assuming $1.7B annual sales level.

Post-Discovery Stage Programs

22% GROWTH OVER THE LAST 12 MONTHS

As of 6/30/2024



n=50

As of 6/30/2025



n=61

- Continued growth and progression of Post-Discovery stage programs
- Increasing diversity of therapy areas within Preclinical programs that include: inflammation, fibrosis, renal, dermatology, oncology, CNS, others
- Total milestones of ~$1.3 billion for Post-Discovery stage programs; includes $700 million of milestones for small molecule ion channel programs

Growth in Post-Discovery Stage Active Programs shown net of attrition

OmniAb

Active Clinical Programs and Approved Products

Number of Active Clinical Programs and Approved Products[1][2]



- 32 active clinical programs and approved products as of 6/30/2025
- One new OmniChicken-derived program entered a first-in-human clinical trial in Q2
  - Seismic Therapeutics' S-4321 Phase 1 trial is designed to provide safety, tolerability, pharmacokinetic, and pharmacodynamic data in healthy volunteers[3]
- We continue to see potential for a total of approximately 5 - 7 new entries into clinical development for novel OmniAb-derived programs this year, which includes two entries as of 6/30/2025

(1) See our SEC filings for Active Clinical Programs and Approved Products definition
(2) Programs shown net of attrition. Clinical attrition in Q2 2025 includes CN1 program returned from Curon to WuXi (CN1 program remains Active Program, now at Preclinical stage) and GEN1078 that entered the clinical development in Q1 2025 and exited the clinic in Q2 2025 (reference clinicaltrials.gov)
(3) Reference NCT06877611, clinicaltrials.gov

OmniAb

Clinical and Commercial-Stage Partner Pipeline[1][2] AS OF 6/30/2025

ONLY PROGRAMS WITH DOWNSTREAM ECONOMICS ARE SHOWN

Phase 1

Johnson & Johnson
JNJ-70218902
TMEFF2 x CD3

Aptevo Therapeutics
Mipletamig
CD123 x CD3

CTTQ Pharma
TQB2223
LAG-3

Servier (Symphogen)
S095018
TIM-3

Servier (Symphogen)
S095024
CD73

Servier (Symphogen)
S095029
NKG2A

Pfizer
PF-08046049[4]
CD228 x 4-1BB

Merck KGaA
M9140[5]
CEACAM-5

Johnson & Johnson
JNJ-79635322
BCMAxGPRC5DxCD3

Zhikang Hongyi (Biocity)
BC3195
CDH3

Gloria Biosciences
GLS-012
LAG3

CessationTherapeutics
CSX1004
Fentanyl

Teva, Fosun
TEV-56278
PD-1 (with IL-2)

Boehringer Ingelheim
BI 765179
CD137 x FAP

Zhikang Hongyi (Biocity)
BC3425
4-1BB

Johnson & Johnson
JNJ-87562761
Undisclosed

Genmab
GEN1057
FAPα x DR4

Merck KGaA
M5542[4]
CTLA4-OX40L

Innolake
ILB2101
CD40

Seismic Therapeutics
S-4321
PD-1 and FcγRIIb

Phase 2

Merck KGaA
M6223
TIGIT
Urothelial carcinoma

Teva
TEV-53408
IL-15
Celiac disease

Phase 1 trial:
Vitiligo

Phase 3

Genmab
Acasunlimab
PD-L1 x 4-1BB
Non-small cell lung cancer

Salubris
SAL003
PCSK9
Hypercholesterolemia and combined hyperlipidemia *(China)*

Immunovant, Hanall Biopharma
IMVT-1402[6]
FcRn
Myasthenia gravis

Potentially registrational trials:
Graves' disease
D2T rheumatoid arthritis
Chronic inflammatory demyelinating polyneuropathy
Sjogren's Disease

Phase 2 proof-of-concept trial:
Cutaneous Lupus Erythematosus

Registration

Hanall Biopharma, Harbour Biomed, Immunovant, CSPC
Batoclimab
FcRn
Myasthenia gravis *(China)*

Phase 3 trial:
Thyroid eye disease *(Japan)*

Potentially registrational trial:
Thyroid eye disease *(US)*

Phase 2 proof-of-concept trial:
Graves' disease *(US)*

Approved

Gloria Biosciences, Arcus Biosciences, Gilead Sciences
Zimberelimab[3]
PD-1
r/r Hodgkin's lymphoma *(China)*
r/r Cervical cancer *(China)*

CStone Pharmaceuticals, Pfizer, EwoPharma
Sugemalimab
PD-L1
Non-small cell lung cancer *(China, UK, and EU)*
Extranodal NK/T-cell lymphoma *(China)*
Esophageal squamous cell carcinoma *(China)*
Gastric or gastroesophageal junction adenocarcinoma *(China)*

(1) Program placement is based on most advanced status in any geography/market/indication
(2) Figure excludes any Clinical and Commercial-Stage Active Partner programs that do not have future or remaining economics to OmniAb, *e.g.*, Teclistamab, Tiragolumab, Etentamig (ABBV-383), AZD0486/TNB-486
(3) Arcus Biosciences and Gilead Sciences are conducting multiple studies using zimberelimab in various oncology therapeutic settings and combinations in the US (see www.arcus.com)
(4) Indicates a trial is active-not recruiting or suspended and/or patients remain on study in follow-up
(5) M9140 is also referred to as Precemtabart tocentecan by Merck KGaA
(6) IMVT-1402 is also referred to as Imeroprubart by Hanall Biopharma

Select Partner Updates

IMMUNOVANT HANALL BIOPHARMA

IMVT-1402
FcRn

A randomized, placebo-controlled, double-blind Phase 3 study to assess the efficacy and safety of IMVT-1402 in patients with mild to severe generalized MG started recruitment in May (NCT07039916).

Additionally, Immunovant has ongoing potentially registrational trials Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Graves' Disease, Difficult to Treat Rheumatoid Arthritis and Sjogren's Disease.

Additionally, a proof-of-concept study has been initiated in a sixth indication, Cutaneous Lupus Erythematosus.

teva

TEV-53408
IL-15

Teva announced that the FDA granted Fast Track designation for investigational TEV-53408, for the treatment of people with celiac disease on a gluten-free diet. TEV-53408 is being evaluated in Phase 2a and Phase 1 clinical trials to assess its efficacy and safety in the treatment of celiac disease and vitiligo, respectively.

TEV-56278
PD-1 (with IL-2)

Teva and Shanghai Fosun Pharmaceutical announced a strategic partnership for the development of TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy. Teva disclosed that the collaboration agreement was established with the goal of accelerating clinical development for TEV-56278, which is in Phase 1 for the treatment of various forms of cancer, including melanoma.

Johnson&Johnson Innovative Medicine

JNJ-79635322
BCMA x GPRC5D x CD3

Johnson & Johnson presented initial Phase 1 results of JNJ-5322, a novel investigational trispecific antibody, in patients with relapsed or refractory multiple myeloma at the ASCO Annual Meeting.

Results showed a 100% overall response rate at the recommended Phase 2 dose of 100 mg in anti-BCMA/-GPRC5D naïve patients, with convenient every 4 week dosing.

Initial data with JNJ-5322 suggest a paradigm shift, offering ORRs similar to CAR-Ts but as an off-the-shelf therapy intended for outpatient dosing.

MERCK

M9140
CEACAM-5

Merck KGaA presented dose optimization results of M9140, an anti-CEACAM5 ADC with exatecan payload at the ASCO Annual Meeting.

Results showed that M9140 demonstrated a predictable, manageable safety profile and promising early clinical activity in heavily pretreated metastatic colorectal cancer (mCRC) patients in the Phase 1 PROCEADE-CRC-01 study. The ORR of 31% (17.2% confirmed) and median progression free survival (mPFS) of 6.9 months at 2.8 mg/kg Q3W compares favorably with current monotherapy SoCs (ORRs 1-2%, mPFS 1.9 – 3.7 months) and recent phase 3 data with trifluridine–tipiracil + bevacizumab (ORR 6.1%, mPFS 5.6 months) in 3L+ mCRC.

Results suggest 2.8 mg/kg as the RP2D for further development in CRC, and other solid tumors.

OmniAb

Reference: Partner disclosures

OmniAb Technologies

TECHNOLOGY OFFERINGS ADDRESSES THE MOST CRITICAL CHALLENGES OF ANTIBODY DISCOVERY

Create

Create Diverse Repertoires of High-Quality Antibodies



Computational Antigen Design & Proprietary Reagents

OmniRat® OmniChicken™ OmniMouse®

Robust Antibodies for Any Target

OmniFlic® OmniClic®

Bispecific Antibody Generation

OmnidAb® OmniTaur™

Novel Scaffolds

Screen

Screen Millions of Cells to Find Potential Therapeutic Candidates

xPloration®



High-Throughput Single Cell Screening



Gel Encapsulated Microenvironment (GEM) Single Cell Screening

Deliver

Further Characterize, Select and Optimize the Right Therapeutic Candidate

- *Custom Bioinformatics*
- *Next Generation Sequencing (NGS) Hit Expansion*



- *Comprehensive Functional Characterization*
- *Proprietary Ion Channel Assays*

- *STR: FC-Silencing Technology**

STR®

OmniDeep® *Suite of in silico tools for discovery and optimization that are woven throughout our various technologies and capabilities. Includes structural modeling, large multi-species antibody databases, molecular dynamics simulations, AI, and machine and deep learning sequence models, and more*

*OmniAb entered into an agreement with mAbsolve Ltd. for STR, mAbsolve's Fc-silencing platform technology, which provides OmniAb with non-exclusive, sublicensable right to incorporate the STR technology with antibodies that have been generated using OmniAb's antibody discovery platform.

What is *Biological Intelligence*™?

- We believe that antibodies generated *in vivo* are superior to ones from other sources because they are **naturally optimized** through an iterative process that preferentially selects for antibodies with excellent specificity and developability profiles
- The ability of the immune system in our engineered transgenic animals to create optimized antibodies for human therapeutics is what we call ***Biological Intelligence***
- We believe this approach **increases the efficiency and probability of success** of therapeutic antibody discovery and may help limit the attrition of antibody product candidates in the clinic

Antibody Repertoires

NUMEROUS OPTIONS AVAILABLE TO ADDRESS DIVERSE PARTNER OBJECTIVES

Host	V genes	Structural and immunological features	Benefits for therapeutics discovery and development
OmniMouse	• Full human V gene diversity • Choice of light chain isotype	• Diverse V gene usage and mixed genetic backgrounds	• Widely accessible and flexible workflows
OmniRat	• Full human V gene diversity • Choice of light chain isotype	• Diverse V gene usage and mixed genetic backgrounds • Distinctive target recognition	• Industry standard • Widely accessible and flexible workflows • Extensive clinical track record
OmniChicken	• Single framework • VH3/VK3 or VH3/VL1	• Evolutionarily divergent host system for robust immune responses	• Diverse and new epitope coverage • High homology targets • Excellent physical properties
OmniFlic	• Full human VH gene diversity with non-diversifying VK3	• Fixed light chain for bispecific applications • Distinctive target recognition	• Bispecific applications leveraging standard IgG format
OmniClic	• Single framework • VH3/non-diversifying VK3	• Fixed light chain for bispecific applications	• Diverse epitope coverage • Excellent physical properties • Ease of manufacturing
OmnidAb	• Single domain human framework, human VH3-23	• Compact scaffold and binding paratope opens new and important opportunities	• Diverse epitope coverage • Unique modalities (NANOBODIES®) • Building Blocks for bi-, multi- specifics and CAR-T
OmniTaur	• Single framework • VH4/VL1	• Ultralong CDR-H3's for enormous structural diversity	• Access cryptic epitopes • Unique modalities (*Picobodies*™) • Building blocks for multispecific molecules

Rodent Platforms

OmniRat™ OmniMouse™

- Endogenous Ig genes inactivated
- Expression of full human V gene diversity
- Streamlined conversion into fully human molecule



Well-validated transgene design utilizes rodent constant regions for robust immune responses from the B-cell repertoire

Geurts et al. ***Science*** 2009
Ménoret et al. ***Eur J Immunol*** 2010
Osborn et al. ***J. Immunol***. 2013

OmniAb™

Our Chicken Platforms - Powered by Evolution

GREATER EVOLUTIONARY DISTANCE YIELDS
GREATER IMMUNOGENICITY AND MORE ANTIBODY DIVERSITY

PRIMORDIAL TARGET GENE
Early form of gene prior to avian/mammalian evolutionary split





Ching *et al.* ***MAbs*** 2018

OmniAb

Common Light Chain Platforms for Bispecific Antibodies

STANDARD IgG FORMAT TO DE-RISK DOWNSTREAM DEVELOPMENT†

OmniFlic™

Rearranged IgVK3-15/JK1



Fixed human VK3-15 light chain expressed with diversifying heavy chain from *any* human germline (44 VHs)

OmniClic®

IgVK3-15/JK1



Fixed human VK3-15 light chain combined with diversifying heavy chain on single scaffold (VH3-23) for superior developability

Target A **Target B**

Facile reformatting via Knob-in-Hole or other Fc-mutations that drive Fc heterodimerization



*Classical IgG-like format**

Bispecific

OmniFlic® & OmniClic® enable IgG-like asymmetric formats

†Gera, Nimish. "The evolution of bispecific antibodies." ***Expert Opinion on Biological Therapy*** (2022)

OmniAb

OmnidAb™



Omni*dAb* is the first and only transgenic chicken producing single domain antibodies (sdAb), a novel class of antibody found naturally in camelids that is being increasingly exploited for a variety of therapeutic applications.

Omni*dAb* is an *in vivo* platform for sdAbs based upon a human VH scaffold that affinity matures in a chicken host environment to provide a functionally diverse immune repertoire unavailable from mammalian systems.

What's driving interest in Omni*dAb*?

*"we are looking to deliver payloads **deep into solid tumors**"*

*"we are building a **panel of multispecific molecules** based on tethered sdAbs"*

*"transporting across the **blood brain barrier** via a highly conserved receptor"*

*"looking for sdAb immune cell engager that can be **linked** to a variety of targeting molecules"*

*"rapid generation of **high affinity human sequence** sdAb candidate molecules"*

What is a Single-Domain Antibody (sdAb)?

ALSO KNOWN AS VHH ANTIBODIES OR NANOBODIES®

Conventional antibody (IgG)

Comprised of 2 heavy chains and 2 light chains



Total MW ~150kD
Binding domain is VH x VL

sdAb

VH domain of HcAb can be expressed independently as an autonomous sdAb unit

Compact format of sdAb (~15kD) opens new and important opportunities

Heavy chain-only antibody (HcAb)

Found naturally in camelids, comprised of 2 heavy chains, no light chain



Total MW ~100kD
Binding domain is VH only

OmniAb

Opportunities for sdAbs in Medicine

PHYSICAL PROPERTIES CAN BE LEVERAGED FOR IMPORTANT APPLICATIONS

Alternate routes of administration
Injectable, inhalable & oral

Penetration + fast/tunable clearance
Blood-brain barrier, tissue, tumor

Imaging/diagnostics/theranostics
Small size compatible with PET/CT imaging radiolabels

Broad therapeutic applications
Central nervous system and neurodegenerative diseases
Infectious and Autoimmune diseases
Cancer (especially bi/multi-specifics & CAR-T)



OmniTaur: Ultralong CDRH3 Create Novel Binding Domains

UNIQUE STRUCTURAL FEATURES OF ULTRALONG H3 ANTIBODIES



- Novel structure may enable targeting epitopes unreachable by standard antibodies
- Long H3 domains can be expressed on human VH framework, or alone as ~5kD Picobodies™

OmniTaur™



Stanfield *et al.* ***Sci Adv*** 2020

OmniAb

Screening Platforms

Create | Screen | Deliver



Our powerful single B-cell screening technologies, ***xPloration*® and GEM assay**, **bypass bottlenecks of hybridoma workflows**

AI-driven multi-parameter screening of **tens of millions** of cells in **hours instead of weeks**

Technologies enable **screening against difficult targets**: GPCRs, ion channels and surface antigens

OmniAb

xPloration Partner Access Program Launch

- xPloration is an innovative and highly leverageable technology
  - Poised to significantly enhance and drive efficiencies in our partners' capabilities for antibody discovery and screening, potentially enabling more OmniAb-derived programs

- Now creating new revenue streams for the business

- Strong initial launch phase, with selection as *"Best-of-Show"* at PEGS conference, and instrument installation just weeks after introduction
  - Potential "right technology at the right time", as our partners and the industry embrace the value of lab automation and instrumentation for big data generation and AI/ML-aided screening and selection

xPloration: AI-Driven Deep Functional Screening

1 | Load the chip



1.5 million, 40 µm microcapillaries
Unique through-hole format

2 | Analyze with Machine Vision

Automated imaging
Computer vision hit detection

3 | Recover hits with laser



Precise laser-based recovery
Single-cell barcoding or pooled

Technical Differentiation of xPloration

INNOVATIVE, HIGH-THROUGHPUT SINGLE B-CELL PLATFORM THAT LEVERAGES ARTIFICIAL INTELLIGENCE – EXPANDS SINGLE CELL SCREENING CAPABILITIES AND SIMPLIFIES WORKFLOWS

Fast and powerful

- Rapid instrument run times of approximately 1.5 hours
  - Short run times enable multiple daily runs
- Screen ten times more single cells per day(1)
- Laser-based recovery process enables large-scale repertoire mining
  - Rapidly sort thousands of live cells via "touchless" method



Simple, easy to use and robust

- Fluidics-free system improves reliability
- AI-assisted image analysis scans thousands of images to find hits
  - Faster and less laborious

(1) Cyto-Mine® Chroma / Beacon® platforms, screening up to 80,000 single cells. Cyto-Mine® Chroma | Fully-automated single cell analysis platform, Optofluidic Product Suite - Bruker Cellular Analysis

Identify The Right Antibody

Our discovery teams are flexibly positioned to work closely with partners to identify the right antibody

- Data from multi-parameter screening and performance assays used in combination with bioinformatics
- NGS hit expansion to identify variant antibodies with improved characteristics
- High-throughput epitope binning and kinetics analysis, and target-specific functional assays
- Proprietary assays for ion channel and transporter targets







OmniDeep® Streamlines and Assists Drug Discovery

- OmniDeep is a suite of *in silico* tools for therapeutic discovery and optimization that are woven throughout our various technologies and capabilities
- These tools include machine vision and sequencing tools for screening, structural modeling for developability filtering, AI and machine learning for assisting discovery and optimization

OmniDeep®

Create	Screen	Deliver
Create Diverse Repertoires of High-Quality Antibodies	***Screen Millions of Cells to Find Potential Therapeutic Candidates***	***Further Characterize, Select and Optimize the Right Antibody***
 *Computational Antigen Design & Proprietary Reagents*	 xPloration® *High-Throughput Single Cell Screening*	• *Custom Bioinformatics* • *Next Generation Sequencing (NGS) Hit Expansion* 

OmniAb®

Business Model

OUR AGREEMENTS ARE STRUCTURED TO ALIGN ECONOMIC AND SCIENTIFIC INTERESTS WITH OUR PARTNERS

Technology licenses include:

- *Upfront/Access fees*
- *Potential Collaboration/Service revenue*
- *Milestones*
- *Royalties on commercial sales*

Illustrative Antibody Deal Structure

Profile A



Collaboration/ Access Fees: ~$1M - $2M

Clinical & Regulatory Milestones: ~$10M - $20M

Royalties: ~Low Single Digits

Profile B



Collaboration/ Access Fees: ~$100k - $500k

Clinical & Regulatory Milestones: ~$5M - $15M

Royalties: ~Mid Single Digits

Notes: Deal Economics have evolved over time. Unique deal structures may also be used (e.g., equity stakes, risk-sharing, buy-in options, etc.)
Not representative of small molecule ion channel technology deal structures

OmniAb

Intellectual Property Advantage

PARTNERS FILING PATENTS ON OMNIAB-DERIVED ANTIBODIES CAN CREATE DIVERSE AND DURABLE ROYALTY STREAMS AND A LENGTHY IP TAIL

Over 300 technology patents issued worldwide

- We maintain a broad intellectual property estate with multiple long duration patent families covering each major element of our technology platform
- Licenses are structured so that royalties are linked to the patents for the antibodies discovered with OmniAb, thereby creating a lengthy coverage tail

Antibody Patent Applications Filed by Partners



~100 patent filings by our partners claiming an OmniAb-derived antibody as primary invention, with expiries up to 2044

OmniAb

Q2 2025 *vs.* Q2 2024 Financial Results

(in millions, except per share data)	Q2 2024	Q2 2025	Variance
License and milestone revenue	$ 3.1	$ 1.2	($ 1.9)
Service revenue	4.2	1.9	(2.2)
xPloration revenue	0.0	0.6	0.6
Royalty revenue	0.3	0.1	(0.2)
Total revenue	**7.6**	**3.9**	**(3.7)**
Cost of xPloration revenue	-	0.3	0.3
Research & development	13.9	10.9	(3.1)
General & administrative	8.0	7.7	(0.3)
Amortization of intangibles	4.5	3.2	(1.3)
Other operating expense (income), net	(2.5)	(1.9)	0.6
Total costs and operating expenses	**23.9**	**20.1**	**(3.8)**
Loss from operations	**(16.3)**	**(16.2)**	**0.1**
Other income (expense), net	0.8	0.5	(0.3)
Loss before income taxes	(15.5)	(15.8)	(0.2)
Income tax benefit (expense)	1.9	(0.1)	(2.0)
Net loss	**($ 13.6)**	**($ 15.9)**	**($ 2.2)**
Net loss per share, basic and diluted	$ (0.13)	$ (0.15)	
Shares used in per share calculation	101.5	106.1	

Table includes rounded figures. Please reference press release dated 8/6/2025 for more detailed information

OmniAb

Balance Sheet

(in millions)	December 31, 2024	June 30, 2025
ASSETS		
Current assets:		
Cash & investments	$ 59.4	$ 41.6
Accounts receivable, net	5.3	2.7
Other current assets	3.4	3.3
Goodwill & intangible assets	222.0	215.6
PPE & leases	33.3	30.8
Other assets	2.1	1.7
Total assets	**$ 325.6**	**$ 295.7**
LIABILITIES AND STOCKHOLDERS' EQUITY		
A/P & accrued expenses	$ 8.4	$ 6.8
Contingent liabilities	1.5	1.7
Deferred revenue	2.5	1.0
Operating lease liabilities	23.2	21.8
Deferred income taxes, net	2.3	2.3
Stockholders' equity	287.6	262.1
Total liabilities and stockholders' equity	**$ 325.6**	**$ 295.7**

Table includes rounded figures. Please reference press release dated 8/6/2025 for more detailed information

- Cash use in the quarter was $2 million
- Primary receipts in the quarter were a milestone payment for GEN1078, acasunlimab and a payment related to asset sale to Angelini

OmniAb

2025 Guidance – No Change from Previous Quarter

- Revenue expected to be in the range of $20 to $25 million
- Operating expense to be in the range of $85 to $90 million
- 2025 cash use expected to be lower than cash use in 2024(1)
- 2025 effective tax rate expected to be approximately 0% due to valuation allowance

(1) Cash use in 2024 was $38.9 million, excluding 2024 ATM issuance

Share Information – as of 6/30/2025

Basic Share Count	**106.4**
Total Earnout Shares	**16.3**
RSU/Options/Warrants	
Employee Unvested RSU/PSU	2.1
Employee Options	24.4
Public Warrants	7.7
Private Warrants	11.3
Total RSU/Options/Warrants	**45.5**
Total Potential Shares	**168.2**

- Basic Shares
  - Common Shares Outstanding/Public Float
- Earnout Shares
  - 50% vest at $12.50, 50% vest at $15.00
  - VWAP of stock for 20 out of 30 consecutive trading days at each respective level for vesting to occur
  - Expire 11/1/27
- Warrants
  - Expire 11/1/27, $11.50 strike price

Our Key Areas of Focus

Partnered Pipeline Development, Expansion and Advancement

Expanding the Reach and the Scalability of our Platform

Efficient Operations and Workflow Versatility Initiatives

New Technology Development and Launches

We leverage a **highly scalable business** where investments in technologies and innovation are informed by discovery relationships with our partners

For more information, please visit www.omniab.com